Entering text into the input field will update the search result below

Virobay on deck for IPO

Oct. 07, 2014 9:54 AM ETAbbVie Inc. (ABBV) StockCELG, JNJ, NVS, PFE, LLY, MRK, HSP, AVNR, PLUR, XNPT, NGSX, TKPHF, MNOV, BDRX, ACGN, IPCI, TAK, FBIO, BLRX, CANF, RDHL, SNGX, ABBV, VBLT, DERM-OLDBy: Douglas W. House, SA News Editor
  • Menlo Park, CA-based Virobay (NASDAQ:VBAY) is set for its IPO of 3.8M shares at $12 - 14.
  • The clinical stage biopharmaceutical firm develops drugs based on its cysteine cathepsin platform. Cysteine cathepsins are important enzymes in the biology of many diseases. The company believes that inhibiting these enzymes produces safer, more effective therapies. It currently focuses its efforts on inhibitors of cathepsins S and B.
  • Its lead product candidates are cathepsin S inhibitors: VBY-036 for neuropathic pain and Crohn's disease and VBY-891 for psoriasis. Phase 2 development for all three indications should commence in 1H 2015 which means that meaningful product revenues are far in the distance.
  • In 2013, the company generated $9.9M in collaboration revenue. Its operating loss was ($2.3M). In 1H 2015, collaboration revenue dropped to $1.1M and the loss from operations increased to ($3.6M).
  • S-1
  • Crohn's disease-related tickers: (ABBV -1.6%)(MRK -1.2%)(RDHL +0.4%)(VBLX)(OTCPK:TKPHF)(TKPYY)(CNDO +1.1%)(SNGX)(PSTI +2.3%)
  • Neuropathic pain-related tickers: (DARA -4.4%)(AVNR -3.4%)(ZLCS +0.9%)(IPCI -2%)(BLRX -1.9%)(MNOV +0.6%)(PFE -0.3%)(NGSX)
  • Psoriasis-related tickers: (DERM -0.5%)(NVS -2.5%)(CELG -1.4%)(LLY -1.3%)(CANF -2.3%)(IDRA -1.4%)(JNJ -0.8%)(XNPT +0.5%)(HSP -0.2%)

Recommended For You

More Trending News

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABBV--
AbbVie Inc.